Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
LORFAN vs KLOXXADO
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Lorlatinib is an ATP-competitive inhibitor of anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) tyrosine kinases. It inhibits phosphorylation of ALK and ROS1, leading to apoptosis and cell cycle arrest.
KLOXXADO (flumazenil) is a benzodiazepine antagonist that competitively inhibits the activity at the benzodiazepine binding site on the GABA-A receptor, thereby reversing the effects of benzodiazepines.
FDA-approved for treatment of ALK-positive metastatic non-small cell lung cancer (NSCLC) in patients who have progressed on prior ALK inhibitors,Off-label: ROS1-positive metastatic NSCLC
Reversal of conscious sedation induced by benzodiazepines,Management of benzodiazepine overdose,Off-label: reversal of benzodiazepine effects in hepatic encephalopathy
12 mg orally three times daily; titrate to 24 mg twice daily after 14 days based on response and tolerability.
5 mg intranasally as a single dose; may repeat once after 2-3 minutes if response inadequate.
Terminal elimination half-life is 2-3 hours in adults with normal renal function; prolonged in renal impairment (up to 20 hours in severe impairment).
Terminal elimination half-life is approximately 2 hours (range 1-4 hours); clinical context: short half-life supports rapid reversal of opioid effects but requires monitoring for renarcotization, especially with long-acting opioids.
Primarily metabolized by CYP3A4 and UGT1A4. Lorlatinib is a substrate of P-glycoprotein.
Hepatic metabolism via CYP1A2 and CYP3A4; undergoes extensive first-pass metabolism; major metabolites are inactive or less active.
Primarily renal excretion (90-95% as unchanged drug); minimal biliary/fecal elimination (<5%).
Hepatic metabolism primarily via CYP3A4 to inactive metabolites; renal excretion accounts for <1% of unchanged drug; fecal excretion accounts for approximately 50-60% of the dose as metabolites.
Approximately 20-30% bound to plasma proteins, primarily albumin.
Approximately 80% bound to plasma proteins, primarily albumin.
2.0-3.0 L/kg, indicating extensive distribution into tissues.
Volume of distribution is approximately 2-4 L/kg; high Vd indicates extensive tissue distribution, which is consistent with rapid redistribution from brain to peripheral tissues, contributing to its short duration of action.
Subcutaneous: approximately 80-100%; intramuscular: approximately 80%; intravenous: 100%.
Intranasal bioavailability is approximately 40-50% relative to intravenous administration; gastrointestinal absorption is limited due to first-pass metabolism, so oral bioavailability is <1%.
No adjustment required for GFR ≥ 30 m L/min; avoid use if GFR < 30 m L/min.
No dose adjustment required for renal impairment.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce to 12 mg once daily; Child-Pugh Class C: not recommended.
No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh A or B); severe hepatic impairment (Child-Pugh C) has not been studied, use with caution.
Not established for age < 18 years.
Weight ≥30 kg: 5 mg intranasally as single dose; weight 10-30 kg: 2.5 mg intranasally as single dose; may repeat once after 2-3 minutes if needed.
No specific dose adjustment; monitor renal function and tolerability closely due to age-related decline in renal function.
No specific dose adjustment; elderly patients may be more sensitive to adverse effects, monitor for excessive sedation or respiratory depression.
None.
None.
Hepatotoxicity: Monitor liver enzymes monthly for first 3 months, then periodically.,Interstitial lung disease/pneumonitis: Withhold and evaluate.,Hyperlipidemia: Monitor serum cholesterol and triglycerides; manage with lipid-lowering agents.,CNS effects: Including seizure, hallucinations, cognitive impairment; dose adjust or withhold.,AV block: Monitor ECG; withhold in second- or third-degree AV block.,Fetal harm: Can cause fetal harm; advise effective contraception.
Risk of seizures, especially in patients with physical dependence on benzodiazepines, concurrent tricyclic antidepressant overdose, or history of seizures,Do not use for diagnostic purposes in suspected seizure disorders,May cause panic attacks in patients with anxiety disorders,Monitor for resedation due to shorter duration of action than benzodiazepines
Concomitant use of strong CYP3A4 inducers,Concomitant use of strong CYP3A4 inhibitors (avoid, or reduce dose if unavoidable)
Known hypersensitivity to flumazenil or benzodiazepines,Patients receiving benzodiazepines for control of life-threatening conditions (e.g., increased intracranial pressure, status epilepticus),Evidence of serious tricyclic antidepressant overdose
Take on empty stomach with water only. Must follow a low-fat diet (<20% of total calories from fat) throughout treatment. Avoid grapefruit and grapefruit juice (CYP3A4 inhibition). Avoid alcohol due to hepatotoxicity risk.
No known food interactions with Kloxxado. Naloxone is not affected by food intake. Avoid alcohol or sedatives as they may exacerbate opioid effects.
Lorlatinib is embryotoxic and fetotoxic in animal studies. In pregnant rats, malformations (including cardiovascular and skeletal) and fetal growth restriction observed at maternal exposures below human AUC. No human data. Avoid in pregnancy; if used, advise effective contraception.
Pregnancy category D: Positive evidence of human fetal risk in first trimester (increased risk of oral clefts), second and third trimesters (risk of maternal and neonatal respiratory depression, neonatal withdrawal syndrome). Avoid in pregnancy unless benefit outweighs risk.
No human data on lorlatinib in breast milk. Animal studies show excretion in rat milk. M/P ratio unknown. Due to potential for serious adverse reactions in nursing infants, advise not to breastfeed during treatment and for at least 11 days after last dose.
Excreted in breast milk; M/P ratio unknown. Potential for infant sedation and withdrawal. Use caution; consider alternative agents or monitor for drowsiness and feeding difficulties.
Physiologic changes in pregnancy (increased volume of distribution, enhanced hepatic metabolism) may reduce lorlatinib exposure. Monitor therapeutic response and toxicity. Consider dose adjustment based on tolerability (increase if subtherapeutic, but safety not established). No specific dose recommendations due to lack of human data; hold if severe toxicity.
No standard dose adjustment recommended; however, pharmacokinetic changes (increased volume of distribution, altered clearance) may require higher or more frequent dosing to maintain efficacy. Individualize based on response and tolerance.
LORFAN (lomitapide) is a microsomal triglyceride transfer protein inhibitor used for homozygous familial hypercholesterolemia. Monitor hepatic function monthly due to risk of elevated transaminases and hepatic steatosis. Must be taken with a low-fat diet (<20% of calories from fat) to reduce gastrointestinal adverse effects. Concomitant use with strong CYP3A4 inhibitors is contraindicated. Dose adjustments needed with moderate CYP3A4 inhibitors. Administer with water only, no food, at least 2 hours after evening meal and 2 hours before next meal.
Kloxxado (naloxone) 8 mg nasal spray is FDA-approved for emergency treatment of opioid overdose. Use in patients with known or suspected opioid overdose, including respiratory depression. Onset within 2-3 minutes. May require repeat dosing due to shorter half-life than many opioids. Monitor for withdrawal precipitation. Store at room temperature; protect from light. Train caregivers and patients on proper administration.
Take lomitapide with a low-fat diet; avoid high-fat meals to reduce stomach side effects.,Take the medication with a glass of water only, at least 2 hours after your evening meal and 2 hours before your next meal.,Do not eat grapefruit or drink grapefruit juice while taking this medication.,Inform your doctor immediately if you experience yellowing of eyes/skin, dark urine, or abdominal pain.,You will need regular blood tests to check liver function; do not miss these appointments.,Avoid alcohol consumption during treatment.
Administer as soon as opioid overdose is suspected: unresponsiveness, slow/stopped breathing, or pin-point pupils.,Spray one dose into one nostril; if no response in 2-3 minutes, give second dose in other nostril using a new device.,Call 911 immediately before or after administration; Kloxxado is a temporary measure.,Stay with patient until emergency help arrives; repeat doses may be needed if opioids are long-acting (e.g., fentanyl).,Side effects include acute withdrawal symptoms (nausea, vomiting, sweating, agitation, rapid heart rate).,Store at 68-77°F (20-25°C); do not freeze. Check expiration date.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about LORFAN vs KLOXXADO, answered by our medical review team.
LORFAN is a Opioid antagonist that works by Lorlatinib is an ATP-competitive inhibitor of anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) tyrosine kinases. It inhibits phosphorylation of ALK and ROS1, leading to apoptosis and cell cycle arrest.. KLOXXADO is a Opioid Antagonist that works by KLOXXADO (flumazenil) is a benzodiazepine antagonist that competitively inhibits the activity at the benzodiazepine binding site on the GABA-A receptor, thereby reversing the effects of benzodiazepines.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between LORFAN and KLOXXADO depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of LORFAN is: 12 mg orally three times daily; titrate to 24 mg twice daily after 14 days based on response and tolerability.. The standard adult dose of KLOXXADO is: 5 mg intranasally as a single dose; may repeat once after 2-3 minutes if response inadequate.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between LORFAN and KLOXXADO in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. LORFAN is classified as Category C. Lorlatinib is embryotoxic and fetotoxic in animal studies. In pregnant rats, malformations (including cardiovascular and skeletal) and fetal growth restriction observed at maternal. KLOXXADO is classified as Category C. Pregnancy category D: Positive evidence of human fetal risk in first trimester (increased risk of oral clefts), second and third trimesters (risk of maternal and neonatal respirato. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.